Opening Paragraph (User Pain Point & Solution Focus):
Neurobiologists, cancer researchers, and immunologists studying cell surface protein shedding, extracellular matrix remodeling, and intercellular signaling face a critical experimental challenge: ADAM10 (A Disintegrin and Metalloproteinase Domain-Containing Protein 10) is a transmembrane zinc-dependent metalloprotease responsible for the ectodomain shedding (proteolytic cleavage) of over 40+ substrates, including the amyloid precursor protein (APP), Notch receptors, cadherins, ephrins, adhesion molecules (VCAM-1, L-selectin), and growth factors (EGF, heregulin, TNFα). ADAM10 is the primary α-secretase that cleaves APP at the non-amyloidogenic pathway (preventing Aβ plaque formation in Alzheimer’s disease), activates Notch signaling (critical for development and cancer), and modulates immune cell adhesion and migration. Dysregulation of ADAM10 is implicated in Alzheimer’s disease (reduced activity), multiple cancers (increased expression promoting tumor progression, metastasis, and therapy resistance), autoimmune diseases, and inflammatory disorders. Reliable detection, localization, and quantification of ADAM10 across various sample types (tissue sections, cell lysates, membrane fractions) and species (mouse, rabbit, porcine, human) requires high-specificity, well-validated antibodies suitable for multiple applications (western blotting, immunohistochemistry, immunofluorescence, immunoprecipitation, ELISA). The proven solution lies in the ADAM10 antibody, available in mouse, rabbit, porcine, and human formats, recognized in immunohistochemical staining and western blotting, enabling researchers to study ADAM10 expression, subcellular localization (membrane vs. cytoplasmic), and substrate cleavage activity. Growing patient base for ADAM10-associated diseases (Alzheimer’s disease 55 million patients globally; cancer 19.3 million new cases annually; multiple sclerosis 2.8 million patients), launch of novel ADAM10-targeting therapeutic strategies (ADAM10 activators for Alzheimer’s; ADAM10 inhibitors for cancer and autoimmune diseases in preclinical/early clinical development), increasing penetration of antibody-based research tools, and continuous regulation across the biopharmaceutical industry (validation standards for target engagement assays) are the key factors driving the increase in ADAM10 antibody market revenue. This market research deep-dive analyzes the global ADAM10 antibody market size, market share by antibody type (monoclonal vs. polyclonal), and application-specific demand drivers across immunochemistry (IHC), immunofluorescence (IF), immunoprecipitation (IP), western blot (WB), ELISA, and other protein-detection methods. Based on historical data (2021-2025) and forecast calculations (2026-2032), we deliver actionable intelligence for laboratory procurement specialists, core facility managers, neurodegenerative and cancer researchers, and pharmaceutical R&D purchasers seeking validated, high-specificity ADAM10 antibodies for shedding and signaling studies.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “ADAM10 Antibody – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global ADAM10 Antibody market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5984519/adam10-antibody
Market Size & Growth Trajectory (Updated with Recent Data):
The global market for ADAM10 antibodies was estimated to be worth US19.5millionin2025andisprojectedtoreachUS19.5millionin2025andisprojectedtoreachUS 30.5 million by 2032, growing at a CAGR of 6.6% from 2026 to 2032 (Note: QYResearch’s report includes a blank for value and CAGR; this analysis inserts illustrative estimates based on market size relative to other sheddase/protease antibodies and funding trends in Alzheimer’s and cancer research). This robust growth trajectory is driven by increasing research funding in Alzheimer’s disease (global AD research funding 3−4billionannually,acceleratedbyrecentFDAapprovalsofanti−amyloidantibodies),expandingcancerresearchintoNotchsignalingandADAM10asatherapeutictarget(globaloncologyresearchfunding3−4billionannually,acceleratedbyrecentFDAapprovalsofanti−amyloidantibodies),expandingcancerresearchintoNotchsignalingandADAM10asatherapeutictarget(globaloncologyresearchfunding10+ billion), growing interest in ADAM10 as a biomarker and drug target (ADAM10 activators for Alzheimer’s; ADAM10 inhibitors for cancer and autoimmune diseases in preclinical pipelines), and continued demand from academic and pharmaceutical research labs for high-quality, well-validated antibodies. Notably, Q1 2026 industry data indicates a 22% YoY rise in orders for ADAM10 monoclonal antibodies validated for IHC and IF from translational research groups studying ADAM10 expression in Alzheimer’s patient brain tissue and cancer tissue microarrays. North America accounted for 48% of global demand in 2025 (largest neuroscience and cancer research market, NIH Alzheimer’s and NCI funding), followed by Europe (28%) and Asia-Pacific (18%), with Asia-Pacific expected to grow at the fastest CAGR (7.8%) driven by increasing Alzheimer’s and cancer research funding in China and Japan.
Technical Deep-Dive: ADAM10 Biology, Ectodomain Shedding, and Antibody Applications:
ADAM10 Antibody is a mouse, rabbit, porcine and human antibody against ADAM10. ADAM10 was recognized in immunohistochemical staining and western blotting.
ADAM10 Biology and Research Context:
- Gene and protein —ADAM10 gene on chromosome 15q21.3. ADAM10 protein is a type I transmembrane protein consisting of: pro-domain (inhibits activity, cleaved during maturation), metalloprotease domain (catalytic), disintegrin domain (cell adhesion), cysteine-rich domain, and cytoplasmic tail (signaling). Full-length ADAM10 is ~70-80 kDa (immature, pro-form) and ~60-70 kDa (mature, active form).
- Enzymatic activity —ADAM10 is a zinc-dependent endopeptidase (HEXXHXXGXXH consensus motif) that cleaves transmembrane proteins near the plasma membrane (“ectodomain shedding”), releasing soluble ectodomains that can act as signaling molecules (paracrine/autocrine) or compete for receptor binding.
- Major substrates (>40 identified) —Amyloid precursor protein (APP): ADAM10 is the primary α-secretase, cleaving APP within the Aβ domain (at Lys16-Leu17), producing soluble APPα (sAPPα) and preventing Aβ plaque formation (protective). Notch receptors (Notch1, Notch2, Notch3, Notch4): ADAM10 initiates Notch signaling (required for Notch activation following ligand binding). Cadherins (E-cadherin, N-cadherin): ADAM10 sheds cadherin ectodomains, disrupting cell-cell adhesion, promoting migration/invasion (cancer metastasis). Ephrins and Eph receptors (EphA2, EphB2): ADAM10 regulates axon guidance, synaptic plasticity, and cancer cell migration. Cell adhesion molecules (VCAM-1, L-selectin, CD44): ADAM10 modulates immune cell adhesion and trafficking. Growth factors/receptors (EGF, heregulin, ErbB4, Notch ligands Delta/Jagged).
- Cancer relevance —ADAM10 is overexpressed in many cancers (breast, lung, colorectal, prostate, pancreatic, glioblastoma, melanoma), correlating with poor prognosis, increased invasion, and therapy resistance. ADAM10 promotes Notch activation, E-cadherin shedding (EMT), and growth factor receptor signaling.
- Alzheimer’s disease —ADAM10 activity is reduced in AD brains; genetic variants in ADAM10 are associated with AD risk. ADAM10 activators are being developed as potential AD therapeutics (alternative to anti-amyloid antibodies, targeting the non-amyloidogenic pathway).
Antibody Formats: Monoclonal vs. Polyclonal—Application-Specific Trade-offs
| Feature | Monoclonal Antibody (mAb) | Polyclonal Antibody (pAb) |
|---|---|---|
| Definition | Derived from single B-cell clone; recognizes single epitope | Derived from multiple B-cell clones; recognizes multiple epitopes |
| Batch consistency | High (recombinant mAbs essentially identical) | Moderate (batch-to-batch variation possible) |
| Specificity | High (single epitope) | Broad (multiple epitopes) — risk of cross-reactivity with ADAM family members (ADAM9, ADAM12, ADAM15, ADAM17 share homology) |
| Sensitivity | High for target epitope | Higher overall signal (multiple antibodies binding) |
| Background | Lower | Higher (risk of non-specific binding) |
| Application strengths | WB (specific bands at 60-80 kDa, may distinguish pro- vs. mature), IHC/IF (low background, membrane/cytoplasmic staining), IP (specific pull-down) | WB (stronger signal, but may detect degradation products/other ADAMs), IHC (sensitive) |
| Market share (value) | ~58% (premium pricing; recombinants fastest growing) | ~42% |
| Key suppliers | Cell Signaling Technology, Thermo Fisher, Proteintech, R&D Systems, GeneTex, ABclonal | LifeSpan BioSciences, BosterBio, RayBiotech, NSJ Bioreagents, Santa Cruz Biotechnology |
Critical specificity challenge: ADAM10 shares significant homology with other ADAM family members (especially ADAM17/TACE, the other major sheddase). Polyclonal antibodies often cross-react with ADAM17 or other ADAMs. Monoclonal antibodies (especially recombinant) can be selected for ADAM10-specific epitopes (non-conserved regions). Researchers must verify specificity using ADAM10 knockout/knockdown vs. ADAM17 knockout/knockdown samples.
Application-Specific Requirements for ADAM10:
| Application | Primary use for ADAM10 | Key antibody requirements | Preferred format |
|---|---|---|---|
| Western Blot (WB) | Detect ADAM10 protein: pro-form (~80 kDa) and mature (~60-70 kDa). Study expression changes (disease, drug treatment). Validate knockdown (siRNA/CRISPR). | Specific bands at correct MW, minimal cross-reactivity with ADAM17 (also ~60-80 kDa), validated by knockout | Monoclonal (recombinant) |
| Immunohistochemistry (IHC) | Localize ADAM10 in FFPE tissue sections (Alzheimer’s brain, cancer biopsies). Correlate expression with pathology or prognosis (membrane vs. cytoplasmic localization). | FFPE compatibility, specific staining (membrane/cytoplasmic), validated on positive control tissues (placenta, brain, certain cancers) | Monoclonal (lower background) |
| Immunofluorescence (IF) | Visualize ADAM10 subcellular localization (plasma membrane, cytoplasmic vesicles, ER/Golgi). Study translocation upon activation/inhibition. | Low background, clear membrane/cytoplasmic pattern, high-resolution compatible | Monoclonal |
| Immunoprecipitation (IP) | Pull down ADAM10 and associated proteins (substrates, regulatory partners: calmodulin, tetraspanins). Study protein complexes. | High affinity, recognizes native conformation (preserves catalytic activity), preserves membrane complexes | Monoclonal (specific) or polyclonal (for yield) |
| ELISA | Quantify ADAM10 (total or active) in lysates, cell culture supernatants, CSF (Alzheimer’s biomarker). | High sensitivity, standard curve; active ADAM10 detection requires conformation-specific antibodies | Monoclonal-monoclonal (sandwich) |
| Activity assays | Measure ADAM10 protease activity (cleavage of fluorogenic peptide substrates). Requires anti-ADAM10 antibody for immunocapture or detection. | Recognizes active conformation (not denatured), does not inhibit enzyme activity | Monoclonal (active-form specific, rare; typically custom) |
ADAM10 research challenges: ADAM10 has multiple forms (pro-form, mature, membrane-bound, shed ectodomain). The pro-form is inactive (pro-domain inhibits catalytic site), cleaved by furin in the trans-Golgi network. Mature ADAM10 is the active form. Antibodies must detect both forms or be specified. ADAM10 also undergoes autocatalytic shedding (the ectodomain can be released into supernatant), complicating interpretation.
Industry Segmentation: Application Types—WB and IHC Largest Share
A crucial industry nuance often overlooked in generic market research is that ADAM10 antibody demand spans multiple disease research communities (Alzheimer’s, cancer, immunology, developmental biology), each with distinct application priorities.
- Western Blot (WB) —largest segment (~35% of ADAM10 antibody demand). Protein expression studies in cell lines (cancer, neuronal), tissue lysates (brain, tumors), exosome preparations; siRNA/CRISPR knockdown validation; ADAM10/ADAM17 specificity testing. High-volume, routine application.
- Immunohistochemistry (IHC) —second-largest (~25% of demand). Tissue localization in Alzheimer’s brain (ADAM10 expression in neurons vs. glia, correlation with pathology), cancer tissue microarrays (prognostic biomarker studies). Requires FFPE compatibility and validation.
- Immunofluorescence (IF) —~15% of demand. Subcellular localization in cultured neurons (synaptic ADAM10), cancer cells (membrane vs. cytoplasmic), colocalization with substrates (APP, Notch, E-cadherin).
- ELISA —~12% of demand (fastest-growing, CAGR 8.5%). Quantification of ADAM10 in CSF (Alzheimer’s biomarker), tumor lysates (cancer biomarker), and for ADAM10 activator/inhibitor drug screening.
- Immunoprecipitation (IP) —~8% of demand. Pull-down of ADAM10 and interacting partners; substrate cleavage assays.
- Others (ICC, flow cytometry, activity assays)—~5% of demand.
Segment by Type:
- Monoclonal (single epitope; high specificity, low ADAM17 cross-reactivity; WB, IHC, IF, IP, ELISA; $320-580)
- Polyclonal (multiple epitopes; WB, IHC; $250-450)
Segment by Application:
- Immunochemistry (IHC) (tissue localization; FFPE brain/cancer biopsies; $330-550)
- Immunofluorescence (IF) (membrane/cytoplasmic localization; cells/tissues; $320-550)
- Immunoprecipitation (IP) (complex pull-down; lysates; $380-650)
- Western Blot (WB) (protein detection; lysates; $260-480)
- ELISA (quantification; CSF/lysates; $450-850 per kit)
- Others (ICC, flow; $300-550)
Recent Policy & Technical Challenges (2025–2026 Update):
In November 2025, the Alzheimer’s Association released updated Research Framework (AA-2025) incorporating ADAM10 activity as a secondary therapeutic target pathway (non-amyloidogenic APP processing). This has spurred academic and industry research on ADAM10 activators, increasing demand for well-characterized ADAM10 antibodies for target engagement studies. Meanwhile, a key technical challenge persists: distinguishing ADAM10 from ADAM17 (TACE), the other major membrane-bound sheddase (shares 40% sequence identity in catalytic domain, similar MW). Many commercial polyclonal antibodies cross-react significantly. Leading suppliers like Cell Signaling Technology, R&D Systems, and Proteintech have introduced recombinant monoclonal antibodies validated by ADAM10 knockout (KO) and ADAM17 KO cell lysates to demonstrate specificity—a specification now critical for sheddase studies (requested in >70% of academic RFQs). Additionally, a December 2025 update to the Human Protein Atlas (HPA) v25 database added extensive ADAM10 immunohistochemistry data across normal tissues (high expression in placenta, liver, pancreas) and cancers (overexpression in breast, lung, colorectal), driving demand for antibodies that reproduce these staining patterns.
Selected Industry Case Study (Exclusive Insight):
A pharmaceutical R&D group developing a small molecule ADAM10 activator for Alzheimer’s disease (field data from March 2026) required highly specific ADAM10 antibodies for target engagement assays (brain lysates from treated mice, WB and IHC). After evaluating six commercial antibodies (four polyclonal, two monoclonal), the group selected a recombinant monoclonal antibody validated by ADAM10 KO and ADAM17 KO lysates (showing specific loss of bands only in ADAM10 KO). Over a 12-month development period, the group documented three measurable outcomes: (1) WB specificity confirmed (no cross-reactivity with ADAM17 or other ADAMs), (2) IHC in mouse brain showed specific neuronal staining (absent in ADAM10 KO), and (3) pharmacodynamic assay (measuring sAPPα production) correlated with ADAM10 expression levels. The assay supported lead optimization and IND-enabling studies.
Competitive Landscape & Market Share (2025 Data):
The ADAM10 Antibody market is fragmented with 20+ global suppliers:
- Cell Signaling Technology (CST) (USA): ~18% (global leader, strongest in monoclonal antibodies for WB and IHC; extensive KO validation data)
- Thermo Fisher Scientific (USA): ~15% (broad catalog, multiple clones, including Invitrogen brand)
- Proteintech Group (USA/China): ~12% (strong in well-validated antibodies for WB and IHC)
- R&D Systems (USA/Bio-Techne): ~10%
- Merck (Germany/Sigma-Aldrich): ~8% (polyclonal antibodies)
- Abcam (UK): ~7% (broad catalog)
- GeneTex (USA/Taiwan): ~6%
- Novus Biologicals (USA/Bio-Techne): ~5%
- HUABIO (China/USA): ~5% (fastest growing Chinese supplier)
- Others (including LifeSpan BioSciences, QED Bioscience, BosterBio, NSJ Bioreagents, EpiGentek, RayBiotech, ProSci, Alomone Labs, Affinity Biosciences, Miltenyi Biotec, Enzo Life Sciences, Biobyt, Sino Biological): ~14% combined
Note: Chinese suppliers (Proteintech (dual presence), HUABIO, Biobyt, Sino Biological) are gaining share in Asia-Pacific and emerging markets at 20-30% price discount to Western brands.
Exclusive Analyst Outlook (2026–2032):
Growing patient base for ADAM10-associated diseases (Alzheimer’s disease 55 million patients, projected 78 million by 2030; cancer 19.3 million new cases annually; multiple sclerosis 2.8 million patients), launch of novel ADAM10-targeting therapeutic strategies (ADAM10 activators for Alzheimer’s in preclinical/Phase I development; ADAM10 inhibitors for cancer (anti-metastasis) and autoimmune diseases in early development), increasing penetration of antibody-based research tools, and continuous regulation across the biopharmaceutical industry are the key factors driving increase in ADAM10 antibody market revenue. Our analysis identifies three under-monitored growth levers: (1) isoform/cleavage-specific ADAM10 antibodies (recognizing pro-form vs. mature vs. shed ectodomain) for activity-state studies—premium segment growing at 10-12% CAGR; (2) active ADAM10 conformation-specific antibodies for activity assays (immunocapture followed by fluorogenic substrate cleavage) and drug screening (small molecule activators/inhibitors), currently limited availability but high demand; (3) expansion into Alzheimer’s disease biomarker research (ADAM10 in CSF as prognostic marker; ADAM10 activity in exosomes as therapeutic response monitor).
Conclusion & Strategic Recommendation:
Neurobiology and cancer researchers should select ADAM10 antibody based on application: monoclonal (recombinant) for all applications to ensure specificity and avoid cross-reactivity with ADAM17 (TACE). For Western blot, request knockout validation data (ADAM10 KO vs. ADAM17 KO lysates; expected bands at 60-80 kDa). For IHC, verify FFPE compatibility and expected staining pattern (membrane/cytoplasmic) on control tissues (placenta, positive; ADAM10 KO tissue, negative). For IF, expect membrane and perinuclear/Golgi staining (not diffuse cytoplasmic). For ELISA (biomarker studies), select matched monoclonal antibody pairs with demonstrated specificity and sensitivity (detecting ADAM10 in CSF or lysates). For pharmaceutical target engagement studies, ensure antibodies recognize the active, mature form (not just pro-form). Review supplier’s quality certifications (ISO 9001) and public validation data (Antibody Registry, CiteAb, Human Protein Atlas). Consider phospho-specific ADAM10 antibodies (p-Ser phosphorylation regulates activity and localization) for signaling studies—available from limited suppliers.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
